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Evidence indicates that leucine-rich repeat kinase 2 (LRRK2) controls multiple processes
in neurons and glia cells. Deregulated LRRK2 activity due to gene mutation represents
the most common cause of autosomal dominant Parkinson’s disease (PD). Protein
kinase A (PKA)-mediated signaling is a key regulator of brain function. PKA-dependent
pathways play an important role in brain homeostasis, neuronal development, synaptic
plasticity, control of microglia activation and inﬂammation. On the other hand, a decline
of PKA signaling was shown to contribute to the progression of several neurodegenera-
tive diseases, including PD. In this review, we will discuss the accumulating evidence
linking PKA and LRRK2 in neuron and microglia functions, and offer an overview of the
enigmatic cross-talk between these two kinases with molecular and cellular implications.
Introduction
Leucine-rich repeat kinase 2 (LRRK2), a gene mutated in autosomal dominant Parkinson’s disease
(PD) and a risk locus for sporadic PD [1,2], encodes a large and complex protein (Figure 1A) with
dual enzymatic function. The presence of serine–threonine kinase and GTPase activities supports a
role for LRRK2 in intracellular signaling cascades. Moreover, distinct repeats, including ankyrin,
leucine-rich and WD40, present at the N- and C-termini indicate that LRRK2 also acts as scaffold for
the assembly of signaling complexes [3]. LRRK2 mutations are clustered within the enzymatic core of
the protein, with disease-segregating mutations in the ROC/GTPase (R1441C/H/G and N1437H),
COR (Y1699C) and kinase (G2019S and I2020T) domains. The observation that all segregating muta-
tions increase LRRK2 cellular activity towards its physiological substrates (LRRK2 itself and Rab pro-
teins) [4,5] and equally impair LRRK2-dependent cellular processes, such as clearance of
Golgi-derived vesicles [6], suggests that LRRK2 signaling cascades are probably in the same way
affected by mutations. LRRK2 has been linked to distinct signaling cascades, including MAPK [7],
Rac/PAK [8,9], Wnt [10], Akt [11], TLR (reviewed in ref. [12]) and cAMP–PKA (protein kinase A)
[13,14] pathways. All these pathways can affect multiple cellular processes, but those in which LRRK2
has been convincingly associated are autophagy, cytoskeletal dynamics, membrane trafﬁcking, mito-
chondria and inﬂammation (reviewed in ref. [15]). Here we will discuss the emerging evidence placing
LRRK2 within the cAMP–PKA signaling pathway and the cellular implications of LRRK2–PKA cross-
talk in neurons and microglia cells.
Cellular consequences of PKA–LRRK2 interaction
PKA (or cAMP-dependent protein kinase) is a tetrameric enzyme composed by a dimeric regulatory
subunit (R) (type I or type II) bound to two catalytic subunits (C). Co-operative binding of cAMP
molecules to the four binding sites on the R subunit dimer leads to the dissociation of C subunits and
subsequent activation of enzymatic activity [16]. The tightly regulated spatiotemporal control of PKA
activity within speciﬁc cellular sites is achieved through interaction with A-kinase anchoring proteins
(AKAPs). AKAPs bind the RII subunit dimer and sequester inactive PKA close to its substrates/effec-
tors, thus promoting the phosphorylation of local substrates during the activation state of the enzyme.
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PKA is part of a multifunctional complex composed of signaling molecules, such as phosphatases (PPs) and
phosphodiesterases (PDEs), crucial for signaling compartmentalization and regulation of PKA activation state
(Figure 1B) [17]. In neurons, cAMP–PKA signaling is a key regulator of short- and long-term synaptic plasti-
city (for a comprehensive review, see ref. [18]), whereas in microglia cells it plays an important role as a nega-
tive regulator of inﬂammation [19–21].
In 2014, Parisiadou et al. [13] observed that medium spiny neurons of Lrrk2 knockout mice exhibit abnor-
mal morphology of dendritic spines, which appeared thinner than those of the wild type. Coherently, they
found impaired postsynaptic transmission in P15 striatal slices of knockout compared with the wild-type mice.
Interestingly, another group did not observe defects in synaptic transmission in acute slices from 3- to 6--
month-old Lrrk2 knockout mice, hinting the possibility that LRRK2 activity at dendritic spines is important
during the early phases of development [22]. The postsynaptic abnormalities observed by Parisiadou et al. are
correlated with an abnormally active PKA with augmented GluR1 and CREB phosphorylation in Lrrk2 knock-
out mice [13]. It is well established that GluR1 and CREB phosphorylated by PKA are critical for spine matur-
ation and neuron development and plasticity [23,24]. Their results indicate that LRRK2 likely acts upstream of
PKA and negatively controls PKA activity, thus modulating neuronal functions. Further supporting a role for
LRRK2 upstream of PKA, Lrrk2 knockout neurons also displayed increased coﬁlin phosphorylation, which
affects on actin cytoskeleton dynamics and may explain the spine phenotype observed by the authors [13].
Phosphorylation of coﬁlin is executed by LIMK1, whose activity is controlled, in part, by PKA phosphorylation
[25]. It is interesting to note that we recently reported a link between LRRK2 and LIMK1, which is directly
phosphorylated by PAK6, an LRRK2 interactor that promotes actin cytoskeleton remodeling [9]. At the
molecular level, LRRK2 interacts with the PKA RIIβ regulatory subunit, and the interaction occurs between
LRRK2 GTPase/ROC domain and RIIβ-dimerization domain. RIIβ-dimerization domain has been shown to be
essential for RII–AKAP interaction [26] and deletion of N-terminal 2–5 residues of RIIβ prevents its interaction
with LRRK2, suggesting that LRRK2 may operate as AKAP. The engagement of ROC domain in heterologous
protein interactions is emerging as a common theme in LRRK2 biology, suggesting that ROC, likely in its
Figure 1. LRRK2 and PKA proteins.
(A) LRRK2 protein contains different domains: Armadillo (ARM), Ankyrin (ANK), leucine-rich repeat (LRR), Ras in complex
protein (ROC), C-terminal of Roc (COR), Kinase (KIN) and WD40. S910/S935 between ANK and LRR and S1444 in the ROC
domain are phosphorylated by PKA. (B) PKA is a tetrameric enzyme composed by a R dimer (type I or type II) bound to two C
subunits. Intracellular increment of cAMP induces the release and activation of C subunits. PKA enzyme is targeted to speciﬁc
cellular organelles or membranes through interaction with A-kinase anchor proteins (AKAPs). PKA is present in a
multifunctional protein complex associated with PP and PDEs.
262 © 2017 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society
Biochemical Society Transactions (2017) 45 261–267
DOI: 10.1042/BST20160396
guanine nucleotide-bound state, is competent to recruit its signaling partners [9,27–31]. Interestingly, immu-
nostaining of endogenous proteins in Lrrk2 knockout neurons reveals mislocalization of RIIβ in dendritic
spines compared with wild-type neurons [13]. Together, these observations indicate that LRRK2 regulates PKA
activity by controlling PKA subcellular localization acting as dendritic AKAP or AKAP-like. Supporting this
idea, neurons derived from mice deﬁcient for MAP2, a well-described dendritic AKAP, also display increased
RIIβ localized in dendritic spines and enhanced phosphorylation of GluR1 [32]. In summary, these results
suggest that LRRK2 controls PKA activation within dendritic spines, possibly acting as an additional AKAP.
Whether LRRK2 controls PKA activity through the modulation of cAMP local concentration by inﬂuencing
the activity of adenylyl cyclases or PDEs is not known at present. Of note, impaired LRRK2–PKA interaction
due to LRRK2 mutation in the ROC domain compromises the signaling at dendritic spines upon dopamine
stimulation [13], suggesting that deregulation of this pathway may have pathological relevance.
In a broader contest, deregulation of PKA signaling has been previously linked to PD. Inhibition of cAMP
degradation by Rolipram, a PDE4 inhibitor, and overactivation of PKA signaling signiﬁcantly attenuate
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion in the striatum and loss of
dopaminergic neurons in the substantia nigra [33]. Moreover, neuronal cells with reduced expression of
endogenous PINK1 displayed mitochondrial fragmentation, increased mitochondria-derived superoxide and
cellular death, phenotypes that can be rescued by PKA activators or transient expression of AKAP1 that targets
endogenous PKA to mitochondria [34]. BE(2)-M17 neuroblastoma cells deﬁcient for PINK1 also exhibited
reduction in Drp-1 PKA-mediated phosphorylation, which is important for mitochondrial function [35]. Taken
together, these observations suggest that downregulation of cAMP–PKA signaling may affect neuronal func-
tionality at different levels, which may converge into a common pathological outcome.
LRRK2 has been shown to regulate PKA-dependent pathways also in microglia cells. Recently, we demon-
strated that primary mouse microglia with Lrrk2 genetic deletion and immortalized BV2 microglia upon
LRRK2 pharmacological inhibition exhibit increased PKA-mediated phosphorylation of nuclear NF-κB p50
subunit [14]. NF-κB p50:p50 homodimer phosphorylated by PKA is constitutively imported into the nucleus
[36], possesses a high afﬁnity for DNA [21] and is essential to repress the transcription of NF-κB target genes
in the absence of extracellular stimuli [37]. Supporting our results, Kim et al. [38] showed that BV2 cells with
LRRK2 knockdown display reduced NF-κB transcription activity and increased p50:p50 homodimer bound to
NF-κB target sites compared with wild-type cells, further supporting the notion that LRRK2 controls NF-κB
Figure 2. Cellular implication of LRRK2–PKA pathways.
Medium spiny neurons and microglia with Lrrk2 genetic deletion exhibit enhanced PKA-dependent signaling. Lrrk2−/− neurons
report abnormal synaptic transmission with increased GluR1 phosphorylation and reduced spine area and length compared
with Lrrk2+/+ neurons. Lrrk2−/− microglia display reduced activation mediated by α-synuclein ﬁbrils or LPS compared with
Lrrk2+/+ cells with increased phosphorylation and binding of p50 to NF-κB target sequences.
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p50 inhibitory signaling. Different groups found a reduced inﬂammation in microglia cells with LRRK2 knock-
down or pharmacological inhibition after inﬂammatory stimuli [14,38–40]. In this regard, we propose that the
enhanced phosphorylation of NF-κB p50 inhibitory subunit bound to DNA might be one molecular mechan-
ism underlying the reduction in NF-κB target genes transcription upon inﬂammatory stimuli. An abnormally
higher proportion of NF-κB p50 phosphorylated in the nucleus of LRRK2 knockout or LRRK2-inhibited cells
may hamper the binding to DNA of NF-κB p65:p50 heterodimer and the activation of gene transcription upon
inﬂammatory priming. Based on these ﬁndings, we predict that an increase in LRRK2 kinase activity, due to
pathological mutations, may attenuate PKA-mediated p50 phosphorylation and its binding to NF-κB target
sites, promoting the binding of active NF-κB p65:p50 and the transcription of pro-inﬂammatory mediators.
This mechanism may result in increased microglia activation and neuroinﬂammation with implication for PD.
Supporting this hypothesis, LRRK2 G2019S mutation carriers exhibit higher levels of peripheral
NF-κB-dependent inﬂammatory cytokines compared with control subjects [41]. It would be interesting to
explore the effect of LRRK2 pathological mutations on PKA-mediated NF-κB inhibitory signaling, using, for
instance, microglia derived from Lrrk2 G2019S knockin mice. Of note, in contrast from what observed in
neurons where LRRK2 regulates PKA activity through localization of RIIβ subunit and independently of its
kinase activity, LRRK2 kinase activity is required for PKA function in microglia cells. Future studies directed at
understanding whether LRRK2 phosphorylates and/or controls the activity of one of the PKA signaling
machinery components will clarify the underlying molecular mechanisms.
Molecular evidence of LRRK2–PKA cross-talk
Early in 2007, Ito et al. [42] observed that HEK293 cells treated with H-89, a moderately selective but highly
potent PKA inhibitor, signiﬁcantly inhibited the incorporation of phosphate into LRRK2 in a dose-dependent
manner. Subsequent studies conﬁrmed that PKA is capable of phosphorylating LRRK2 in vitro and in cells,
providing indications on the speciﬁc phosphorylation sites [43,44]. Li et al. [43] showed that phosphorylation
of S910 and S935 at the N-terminus of LRRK2 is increased upon forskolin (an adenylyl cyclase activator) treat-
ment and is reduced upon PKA pharmacological inhibition. A different study reported that PKA directly phos-
phorylates LRRK2 S1444 in the ROC domain [44]. It is interesting to note that phosphorylation of both S910/
S935 and S1444 promotes LRRK2 binding to 14-3-3 proteins [43–45], chaperones that are crucial to control
the activity of different signaling molecules [46]. Accordingly, multiple lines of evidence indicate that 14-3-3
binding regulates LRRK2 kinase activity [44,47] and/or subcellular localization [48]. In this context, Muda
et al. [44] found that LRRK2 R1441C/G/H pathogenic mutations prevent phosphorylation of S1444 by PKA,
indicating that a substitution of the nearby arginine at position 1441 may disrupt the PKA recognition motif.
Moreover, the authors found that LRRK2 binding to 14-3-3, controlled by PKA phosphorylation at S1444,
negatively regulates LRRK2 kinase activity. These results support the notion that PKA controls LRRK2 kinase
activity by S1444 phosphorylation and subsequent binding of 14-3-3 proteins, and that the pathogenic effect of
ROC mutations may be explained, at least in part, by the downregulation of S1444 phosphorylation. To compli-
cate the scenario, PKA-dependent phosphorylation of S935 also controls LRRK2 binding with 14-3-3 proteins,
and the majority of LRRK2 segregating mutations exhibits reduced levels of S935 phosphorylation and
impaired binding with 14-3-3s [43,45]. In contrast with S1444, PKA-mediated S935 phosphorylation does not
appear to affect LRRK2 kinase activity per se. LRRK2 S910A/S935A immunoprecipitated from MEF (mouse
embryonic ﬁbroblasts) cells retains the ability to phosphorylate Rab8 in vitro to a similar extent as LRRK2 wild
type [47]. Moreover, LRRK2, dephosphorylated at S910/S935 by pharmacological inhibition, displays similar
kinase activity as LRRK2 treated with DMSO [45]. Instead, S910/S935 phosphorylation state profoundly affects
LRRK2 cellular localization [49] and, as consequence, the proximity of the kinase to its physiological substrates.
Supporting this hypothesis, LRRK2 S910A/S935A knockin MEFs display a dramatic reduction in endogenous
Rab10 phosphorylation compared with wildtype cells [47]. The apparent paradox is that the majority of
LRRK2 mutations exhibit reduced S935 phosphorylation [45], altered cellular localization [49] but increased
kinase activity [4,5]. Future studies will hopefully disentangle the precise molecular mechanisms. In addition to
PKA, S935 has been reported to be phosphorylated by other kinases, such as CK1α [50] and IKB kinase family
[51], suggesting a multilayer control that can be cell-type or pathway speciﬁc. Overall, these observations indi-
cate that phosphorylation of S910/S935 and S1444 may affect LRRK2 catalytic activity, cellular localization and
the downstream signaling. Clearly, more investigations are required to clarify the cellular consequences of S910/
S935 and S1444 phosphorylation on LRRK2 pathophysiology.
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Concluding remarks
Recent literature highlights a functional interaction between LRRK2 and PKA with an enigmatic cross-talk
between these two kinases. In the brain, LRRK2 acts upstream of PKA and negatively controls its activity with
apparent different mechanisms. In neuronal cells, LRRK2 seems to operate as AKAP to localize PKA signaling
at the dendritic spines independently of its kinase activity. Instead, in microglia cells, LRRK2 kinase activity
appears to down-regulate PKA signaling through a still unknown mechanism. These observations indicate that
LRRK2-dependent regulation of PKA activity and, more in general, LRRK2 physiological function might be
cell-type speciﬁc. This point seems particularly important, as it may not be appropriate to generalize LRRK2
molecular mechanisms in a cell-type that is not relevant for PD. Understanding whether mutant LRRK2 affects
neurons, microglia or astrocytes homeostasis is an exciting future challenge for the ﬁeld. There is also molecular
evidence that PKA acts upstream of LRRK2 through direct phosphorylation. One limitation of these data,
however, is that it is not clear whether PKA directly phosphorylates LRRK2 in the cellular context, as these
results have been obtained either in vitro or indirectly by increasing cellular cAMP [44,47]. We can speculate
that if PKA is upstream of LRRK2, the decline of PKA signaling observed in PD brains may affect LRRK2
binding to 14-3-3 and, as consequence, its kinase activity or its subcellular localization leading to pathological
events. Instead, if LRRK2 is upstream of PKA, this may result in an alteration of synaptic transmission in
neurons and/or in an exacerbated inﬂammatory response in microglia when LRRK2 is mutated. Overall, these
observations suggest that both directions of LRRK2–PKA interaction might be relevant for the pathogenesis of
the disease. Future studies directed at understanding the precise molecular mechanisms underlying LRRK2–
PKA cross-talk will offer more opportunities to understand the complex LRRK2 pathobiology, with implication
for the translation of LRRK2 inhibition strategies into the clinics.
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